Hongbing Fan

Mar 12, 2024 | dx.doi.org | Zihan Wang |Hongbing Fan |Jianping Wu |Kenneth H. III

Angiotensin converting enzyme 2 (ACE2), best known as the entry receptor of the pandemic’s severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted considerable attention during the outbreak of COVID-19. (1) ACE2 was first discovered in 2000 from a human cardiac left ventricle cDNA library.

Mar 12, 2024 | pubs.acs.org | Zihan Wang |Hongbing Fan |Jianping Wu |Kenneth H. III

Angiotensin converting enzyme 2 (ACE2), best known as the entry receptor of the pandemic’s severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted considerable attention during the outbreak of COVID-19. (1) ACE2 was first discovered in 2000 from a human cardiac left ventricle cDNA library.

Feb 14, 2024 | onlinelibrary.wiley.com | Hongbing Fan |Nan Shang |Sandra Davidge |Jianping Wu

This study aims to investigate the antihypertensive effect of four chicken muscle-derived angiotensin (Ang)-converting enzymes (ACE)-regulating peptides: Val-Arg-Pro (VRP, ACE inhibition), Leu-Lys-Tyr and Val-Arg-Tyr (LKY and VRY, ACE inhibition and ACE2 upregulation), and Val-Val-His-Pro-Lys-Glu-Ser-Phe (VVHPKESF [V-F], ACE2 upregulation) in spontaneously hypertensive rats. Rats (12–14 weeks old) are grouped: 1) untreated, 2) VRP, 3) LKY, 4) VRY, and 5) V-F.